What it sells
Unleash the potential of genomic medicine using AI
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D or business development leadership at biopharma partners (partnership deals).
Trigger: what makes them buy now?
High early-stage drug R&D failure rates (<10% standard success) and need to de-risk and shorten genomic medicine timelines; claims vision of cutting R&D by 6-7 years.
Workflow: what inputs become what output?
In silico prediction of optimal molecular constructs and delivery vectors (e.g. AAV capsids) for a target product profile, validated with external wet labs, delivered as tailored modules.
Economics: what it saves and how it charges
UnverifiedLikely partnership, collaboration and milestone-based deals rather than software subscriptions; no pricing shown.
Distribution: how it reaches customers
Direct partnerships and R&D collaborations with pharma and tech players.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-06 | — | $26M | — | news.google.com |
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.